Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review
Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignan...
Main Authors: | Gilbert Lazarus, Jessica Audrey, Anthony William Brian Iskandar |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2019-10-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | https://www.oncologyreviews.org/index.php/or/article/view/425 |
Similar Items
-
Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
by: Jhe-Cyuan Guo, et al.
Published: (2019-01-01) -
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
by: Qiang Liu, et al.
Published: (2017-01-01) -
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
by: Debasree Banerjee, et al.
Published: (2018-06-01) -
Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01) -
Expression of programmed death-ligand 1 in cutaneous squamous cell carcinoma arising in sun-exposed and nonsun-exposed skin
by: Hiroyuki Goto, et al.
Published: (2020-01-01)